LOGIN OR REGISTER
Course Library

Clinical Convergence: New Management Approaches in Bladder Cancer from Collaborative Care to Immunotherapy

Hematology-Oncology
Curriculum:
Clinical Convergence: New Management Approaches in Bladder Cancer from Collaborative Care to Immunotherapy
Credits:
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
March 21, 2017
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Oncologists and oncology nurse practitioners and physician assistants

Relevant Terms:

Bladder Cancer

Elizabeth R. Plimack, MD, MS

Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center, Temple University Health System
Philadelphia, PA

Elizabeth R. Plimack, MD, MS is associate professor of medical Oncology, chief of the division of genitourinary medical oncology, and director of genitourinary clinical research at Fox Chase Cancer Center. Dr. Plimack received her undergraduate degree from Yale University and completed her medical degree and residency in internal medicine at the New York University School of Medicine. She completed a medical oncology fellowship at the MD Anderson Cancer Center and received a master’s degree in patient-based biologic research from the University of Texas Graduate School of Biomedical Science.
 
Dr. Plimack is an expert on the treatment of genitourinary malignancies with a focus on bladder cancer. Her research effort is directed toward the discovery of novel therapeutic approaches and predictive biomarkers for patients with advanced bladder cancer. She has extensive clinical trial experience with immunotherapies and novel combination therapies, and her worked has been included in numerous peer-reviewed publications.
 
Dr. Plimack serves on the National Comprehensive Cancer Network guidelines panel for bladder cancer, the American Society of Clinical Oncology GU Scientific Program Committee, the Bladder Cancer Advocacy Network Think Tank Steering Committee, and the American Joint Committee on Cancer Urinary Tract Expert Panel. She is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the Society of Urologic Oncology.

Alexander Kutikov, MD

Alexander Kutikov, MD
Associate Professor
Department of Surgical Oncology
Fox Chase Cancer Center, Temple University Health System
Philadelphia, PA

Alexander Kutikov, MD, is a urologic oncologist at Fox Chase Cancer Center in Philadelphia. He received his medical degree from Harvard Medical School and completed urologic surgical training at the University of Pennsylvania in Philadelphia. Following a Society of Urologic Oncology fellowship at the Fox Chase Cancer Center, he remained at Fox Chase on faculty where he is currently an associate professor of urologic oncology in the department of surgery.
 
Dr. Kutikov serves as associate editor of digital media for European Urology journal, co-editor of the News and Topics section of the Urologic Oncology: Seminars and Original Investigations, and associate editor of Elsevier’s Urology Case Reports. He is on the prostate cancer expert panel for the Urology Care Foundation of the American Urological Association and is president-elect of the Young Urologic Oncologists Section of the Society of Urologic Oncology.
 
Dr. Kutikov has authored more than 150 publications and has published chapters in leading textbooks, including the definitive chapter on adrenal disorders in Campbell-Walsh Urology. He has significant interests in harnessing information technology to improve quality of care. He is a co-founder of several ventures and an invited speaker and lecturer across the globe.
1. Appropriately utilize currently approved treatments for advanced or metastatic urothelial bladder cancer to optimize patient outcomes
2. Incorporate neoadjuvant chemotherapy into the multidisciplinary management of patients with advanced or metastatic urothelial bladder cancer
3. Describe how emerging immunotherapies can be incorporated for management of patients with advanced or metastatic urothelial bladder cancer
4. Employ a strong patient-provider collaborative approach to managing patients with advanced or metastatic urothelial bladder cancer that includes patient education, engagement, and shared decision making

PHYSICIAN CONTINUING MEDICAL EDUCATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Elizabeth R. Plimack, MD, MS, has affiliations with Acceleron, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Pfizer (Consulting Fees and Contracted Research); Genentech, Novartis, Roche, and Synergene (Consulting Fees); and Aveo, Dendreon, GlaxoSmithKline, Merck, and Peloton (Contracted Research).
  • Alexander Kutikov, MD, has affiliations with Genomic Health, Inc. (Consulting Fees) and Visible Health, Inc. (Ownership Interest).
RMEI Medical Education, LLC
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Marie N. Becker, PhD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Estimated time to complete: 1.0 hour
Media: Internet
 
FEE INFORMATION
There is no fee for this educational activity.
 
COMMERCIAL SUPPORT
This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an independent educational grant from Genentech.
 
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
 
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 		 Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.



 

Schedule an event with a Standardized Patient
×